Area of research
Immunology · Oncology
Research interest
My research focuses on identifying novel cell surface and secreted proteins that govern T cell activation, tolerance, memory, and survival. My career is also dedicated to translating fundamental laboratory discoveries into transformative therapies, primarily in cancer immunotherapy. In 1992, my laboratory published the first proof-of-concept study demonstrating that manipulating the B7-CD28 family, specifically by introducing B7-1 into tumor cells, could enhance anti-tumor immunity.
B7-H3 as a Universal Target for Solid Tumor Therapy: Clinical Promise and Biological Complexity.
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach.
PD-L1 and the dawn of modern cancer immunotherapy.
Spatial Transcriptomics Reveals Differential Inflammatory Pathways in Discoid Lupus Erythematosus and Lichen Planus
The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab.
PD-1H (VISTA) Expression in Cutaneous Squamous Cell Carcinoma Is Correlated with T-Cell Infiltration and Activation
Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance
Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance
Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity.
Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
The CD8α-PILRα interaction maintains CD8<sup>+</sup> T cell quiescence.
Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy.
Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy.
Structural insight into T cell coinhibition by PD-1H (VISTA).
B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
Normalization Cancer Immunotherapy for Melanoma
Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.
PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus.
Calnexin Impairs the Antitumor Immunity of CD4<sup>+</sup> and CD8<sup>+</sup> T Cells.
CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers.
Dendritic cell-associated B7-H3 suppresses the production of autoantibodies and renal inflammation in a mouse model of systemic lupus erythematosus.